Gather in Wuhan for the 2nd Summit on RNA Therapy and Novel Vaccine Industry

As one of the emerging directions in “programmable medicine,” nucleic acid drugs comprise two main technological branches: small nucleic acids and mRNA. Small nucleic acid drugs, compared to existing small molecules and antibody drugs, offer advantages such as rapid target screening, high success rates in research and development, low likelihood of resistance, broader therapeutic areas, and long-lasting effects. They are poised to become the third major category of drugs after small molecules and antibodies.

On August 16-17, 2022, the First VacFuture 2022 (Guangzhou) Summit on RNA Therapy and Novel Vaccine Industry was successfully held in Guangzhou, attracting 913 professional attendees and featuring 55 guest speakers. Concurrently, the Second VacFuture 2023 (Wuhan) Summit on RNA Therapy and Novel Vaccine Industry is scheduled for June 3-4, 2023, in Wuhan, with over 800 attendees and 40 exhibitors expected. The summit will focus on “Small Nucleic Acid Drug Development” and “mRNA Novel Vaccine Research and Development.”

Hosted by: Fung Sheng Biological

Supported by: Shanghai Biopharmaceutical Industry Association, Hubei Bioinformatics Society, Guangdong Medic Valley

Media Partner: RNAScript

Theme: Focusing on RNA Therapy Breakthroughs to Chart the Blueprint for Next-Generation Vaccine Localization Challenges

Date: June 3-4, 2023

Venue: Wuhan Marriott Hotel Optics Valley